Journal article

Editorial: Functional Characterization and Pharmaceutical Targets in Common and Rare CFTR Dysfunctions

EK Schneider-Futschik, VH Lobert, JW Wilson

Frontiers in Physiology | FRONTIERS MEDIA SA | Published : 2022

DOI: 10.3389/fphys.2021.830285

Download PDF

University of Melbourne Researchers

Related Projects (1)

Project icon

SYSTEMS PHARMACOLOGY OF CYSTIC FIBROSIS TRANSMEMBRANE REGULATOR CORRECTORS AND POTENTIATORS

Cystic fibrosis is a life limiting disease caused by defective or deficient cystic fibrosis trans-membrane conductance regulator activity. T..

Grants

Awarded by National Health and Medical Research Council

Funding Acknowledgements

Funding ES-F was supported by the NHMRC (Grant ID: APP1157287) and Cystic Fibrosis Australia.

Keywords

2.1 Biological and Endogenous Factors
Rare Diseases
Cystic Fibrosis
32 Biomedical and Clinical Sciences
3 Good Health and Well Being
Life Sciences & Biomedicine
Lung
3208 Medical Physiology
Physiology
Cftr (cystic Fibrosis Transmembrane Conductance Regulator)
Biomarker
Cftr (cystic Fibrosis Transmembrane Regulator)
Science & Technology